Uwe Siebert, MD, MPH, MSc, ScD

Prof. of Public Health (UMIT), Adjunct Prof. of Health Policy and Management (Harvard Univ.)
UMIT
UMIT, Dept. of Public Health, Health Services Research and Health Technology Assessment
Eduard-Wallnoefer-Zentrum 1
Hall in Tirol (Austria) / Boston (USA) Austria 6060 / 02115
Email: uwe.siebert@umit.at


Biographical Sketch: Prof. Uwe Siebert, MD, MPH, MSc, ScD, Professor of Public Health, is the Chair of the Department of Public Health, Health Services Research and Health Technology Assessment at UMIT - University for Health Sciences, Medical Informatics and Technology in Austria and the Director of the Division for HTA in the ONCOTYROL – Center for Personalized Cancer Medicine in Austria. He is also Adjunct Professor of Health Policy and Management at the Harvard T.H. Chan School of Public Health and Director of the Program on Cardiovascular Research at the Institute for Technology Assessment and Department of Radiology at the Massachusetts General Hospital, Harvard Medical School, Boston. Prof. Siebert worked as a physician in international public health projects. He then earned an MPH (Univ. Munich), MSc in Epidemiology (Harvard Univ.), and ScD in Health Policy and Management (Harvard Univ.), and was Director of the Bavarian Public Health Research & Coordinating Center. Since 2014, he teaches the Summer Course on ‘Decision Analysis in Clinical Research’ at the Harvard T.H. Chan School of Public Health. His research interests include applying evidence-based quantitative, qualitative and translational methods from public health and decision sciences in the clinical context of routine health care and in the framework of HTA. His current substantive research focuses on cancer, cardiovascular disease, hepatitis C and other areas. He is Clinical Guideline Commissioner of GMDS for the AWMF in Germany, Co-Chair of ISPOR-SMDM Modeling Task Force, and Co-Chair of SMDM’s Methodology Section. He was a member of the International Expert Committee Advising the Institute for Quality and Efficiency in Health Care (IQWiG) and has served as Vice-President of SMDM. He has worked with several HTA and Government Agencies, advises institutions regarding the conduction of HTA, has authored more than 300 publications, and is a member of several Journal Editorial Boards.

Papers:
1B-2 IMPROVING CERVICAL CANCER PRIMARY SCREENING AND DIAGNOSTIC FOLLOW-UP IN AUSTRIA – A DECISION-ANALYTIC BENEFIT-HARM ANALYSIS 1B-5 HEALTH-ECONOMIC EVALUATION OF HPV-BASED CERVICAL CANCER PRIMARY SCREENING COMPARED TO CYTOLOGY OR P16/KI-67 DUAL-STAINING – A DECISION-ANALYSIS FOR THE AUSTRIAN HEALTH CARE CONTEXT 2E-1 LONG-TERM EFFECTIVENESS AND COST EFFECTIVENESS OF DIFFERENT ANTIVIRAL TREATMENTS FOR CHRONIC GENOTYPE-1 HCV INFECTION IN GERMANY INCLUDING OMBITASVIR/PARITAPREVIR/RITONAVIR AND DASABUVIR DIRECT ANTIVIRAL DRUGS FOR THE TREATMENT OF CHRONIC HEPATITIS C PATIENTS WITH GENOTYPE 1 OR 4 IN FRANCE - COST-EFFECTIVENESS OF OMBITASVIR/PARITAPREVIR/RITONAVIR WITH OR WITHOUT DASABUVIR BY FIBROSIS SUBGROUP THE BENEFIT-HARM BALANCE OF PROSTATE CANCER SCREENING IN MEN WITH AVERAGE AND ELEVATED FAMILIAL RISK – PREDICTIONS OF THE ONCOTYROL PROSTATE CANCER OUTCOME AND POLICY MODEL BUDGET IMPACT ANALYSIS INCLUDING OMBITASVIR/PARITAPREVIR/RITONAVIR AND DASABUVIR FOR THE TREATMENT OF CHRONIC HEPATITIS C IN FRANCE AN OVERVIEW OF DIFFERENT MAPPING TECHNIQUES TO DERIVE HEALTH STATE UTILITY VALUES IN MULTIPLE MYELOMA FOR DECISION-ANALYTIC MODELING COSTS OF FIRST-LINE TREATMENT FOR ELDERLY MULTIPLE MYELOMA PATIENTS WHO ARE NOT TRANSPLANT CANDIDATES IN THE SERBIAN HEALTH CARE SYSTEM META-ANALYSIS AND INDIRECT TREATMENT COMPARISON OF SAFETY PROFILES OF BORTEZOMIB- AND THALIDOMIDE-BASED REGIMENS FOR THE FIRST LINE TREATMENT OF ELDERLY TRANSPLANT-INELIGIBLE PATIENTS WITH MULTIPLE MYELOMA TREATMENT STRATEGIES FOR MULTIPLE MYELOMA IN ELDERLY PATIENTS: A NETWORK META-ANALYSIS AM1 SMDM CORE COURSE: INTRODUCTION TO MEDICAL DECISION ANALYSIS (DECISION-ANALYTIC MODELING)